Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: This is a spontaneous report from a contactable consumer, received via the regulatory authority (report number is GB-MHRA-WEBCOVID-202106021957381830-2GUMX). A 34-year-old female patient received the 1st dose of BNT162B2 (Pfizer-BioNTech COVID-19 vaccine, lot# not reported), via an unspecified route of administration, on May 29, 2021, single dose, for COVID-19 immunisation. Medical history included decreased lactation and anxiety. Patient has not had symptoms associated with COVID-19. Patient is not enrolled in a clinical trial. Patient is not pregnant and not currently breastfeeding. Concomitant medication included sertraline taken for anxiety. On Jun 1, 2021, patient experienced kidney pain, urinary tract infection and blood in urine. Medically significant events. The patient underwent lab tests and procedures, which included COVID-19 virus test was No - Negative COVID-19 test and urine sample, with unknown results both on an unspecified date. Outcome of the urinary tract infection: recovering; while of the remaining events were unknown. The clinical course was reported as follows: Strong symptoms of UTI blood in urine and kidney pain. Patient has not tested positive for COVID-19 since the vaccination. No follow-up attempts are possible. Information about batch number cannot be obtained.
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166